Under a tenth of individuals that would benefit from weight-loss injections like Wegovy can access them, caution the WHO as it releases its initial guidance on the drugs.
Considering more than one billion individuals worldwide now obese, it is advocating for broader and more equitable availability to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to universal access to the jabs that can assist patients in reducing significant body mass, explains the body.
GLP-1 Therapy Scarcity
Despite the current most favorable case, the manufacturing of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.
The guideline calls on countries and companies to increase availability, via approaches including patent sharing.
A patent on semaglutide – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Function
These medications mimick a body's own hormone to slow digestion, suppress the appetite and boost feelings of fullness so users reduce food intake.
Patients usually begin shedding pounds within a few weeks of beginning the regular doses.
Research points to patients may see weight return within a year of stopping the medication, as their normal hunger return.
To be carrying excess weight raises your chance for experiencing diseases, such as diabetes, heart disease, stroke, and specific cancers.
Obesity impacts people in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
